Post by i-Pharm Consulting

The May edition of i-Pharm Insights is here! 📰 This month, we're covering the oral GLP-1 race: two once-daily obesity pills on the US market simultaneously for the first time, with a global rollout already underway. We look at: → What separates the two pills, and why it matters commercially → The science behind four decades of work that led to this moment → A $95B market, 25 million Americans on GLP-1s by 2030, and a wave of competitors closing in fast → What it means for Clinical Development, Regulatory Affairs, Medical Affairs, and Market Access & Commercial careers Also check out our hot jobs and the latest at i-Pharm, including a decade at i-Pharm for James McCune and our 2025 Big Billers heading to Tokyo. Read the May issue in full below ⬇️ #GLP1 #Obesity #LifeSciences #Pharma #iPharmInsights